Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma

A window beneath the skin: how computed tomography assessment of body composition can assist in the identification of hidden wasting conditions in oncology that profoundly impact outcomes

“…Of note is the heterogeneity in the prevalence of sarcopenia among cohorts of the same primary cancer site and stage, e.g. 19-71 % in advanced colorectal cancer (54,55) , 33-90 % in metastatic kidney cancer (53)(54)(55)(56) and 21-89 % in advanced pancreatic cancer (57,58) . This large variability could be attributed to the varying cut points used to define sarcopenia; limitations related to sample size; or patient characteristics such as age, sex, ethnicity, BMI and concurrent co-morbidities, thus limiting the ability to draw conclusions as to the true prevalence according to the cancer site.…”

“…Van Vledder et al (54) The Netherlands Advanced/196 19 Lieffers et al (110) Canada Stages II-IV/234 39 Thoresen et al (162) Norway Advanced/50 20 Barret et al (55) France Metastatic/51 71 Thoresen et al (163) Norway and Canada Advanced/77 39 Miyamoto et al (41) Japan Stages I-III/220 25 Reisinger et al (164) The Netherlands Stages I-IV/310 48 Buskermolen et al (88) The Netherlands Metastatic/67 57 Chemama et al (77) France Advanced/97 40 Malietzis et al (165) UK Resectable/763 65 Cann et al (30) USA Stages I-III/3262 42 McSorley et al (69) UK Resectable/322 47 Oesophageal/oesophagogastric cancer Awad et al (118) UK Stages I-III/47 57 Yip et al (85) UK Stages I-III/35 26 Reisinger et al (119) The Netherlands Stages I-IV/123 56 Tamandl et al (28) Austria Non-metastatic/200 65 Tan et al (84) UK Stages I-III/89 49 Anandavadivelan et al (83) Sweden Resectable/72 43 Grotenhuis et al (166) The Netherlands Resectable/120 45 Nishigori et al (167) Japan Resectable/199 75 Elliott et al (40) Ireland Resectable/252 16 Gastric cancer Tegels et al (168) The Netherlands Stages I-IV/152 58 Hayashi et al (13) Japan Advanced/53 70 Nishigori et al (169) Japan Resectable/157 62 Palmela et al (81) Portugal Stages II-III/48 23 Kudou et al (170) Japan Stages I-III/148 28 Lung cancer Baracos et al (27) Canada NSC/stages III-IV/441 47 Stene et al (37) Norway NSC/stages IIIb-IV/35 71 Arrieta et al (171) Mexico NSC/metastatic/84 69 Kim et al (101) Korea SC/stages I-III/149 79 Kidney cancer Antoun et al (73) France Metastatic/55 55 Antoun et al (38) Canada Advanced/80 53 Huillard et al (74) France Metastatic/61 53 Sharma et al (96) USA Metastatic/93 29 Auclin et al (53) France Metastatic/124 90 Cushen et al…”

Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma – Analyses From the German Clinical RCC-Registry

“…3 Over the past decade, the treatment of mRCC has evolved dramatically and has undergone a paradigm shift. The introduction of molecularly targeted agents blocking the vascular endothelial growth factor (VEGF) and the mechanistic target of rapamycin (mTOR) signalling pathways 3,[6][7][8][9] has significantly improved the outcomes of patients with mRCC in clinical trials. 3,10 It also improved overall outcome in the United States, although treatment-specific data are missing.…”

Current status of prognostic factors in patients with metastatic renal cell carcinoma

“…A lot of predictive factors that were associated with worse ORR, shorter PFS or OS have been shown in previous retrospective studies (Table ) . Several studies have focused targeted molecules and their related factors in tumor tissues or serum, such as VEGFRs and tuberous sclerosis complex .…”

“…A lot of predictive factors that were associated with worse ORR, shorter PFS or OS have been shown in previous retrospective studies ( Table 2). [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] Several studies have focused targeted molecules and their related factors in tumor tissues or serum, such as VEGFRs and tuberous sclerosis complex. [18][19][20]30 Although genetic analysis or expression analysis for these molecules seem to be reasonable to identify prognostic markers in patients treated with targeted agents, it has not been so easy to assess this information during real clinical practice yet.…”